XG0201

XG0201 is an exploratory therapeutic candidate currently being investigated in a Phase 0 clinical trial for the treatment of HER2-positive breast cancer with newly diagnosed brain metastases. Developed by researchers at The Third Affiliated Hospital of Zhengzhou University, the drug is being evaluated as an add-on therapy to standard-of-care treatments (such as pyrotinib and capecitabine). The Phase 0 study is a single-center, single-arm exploratory trial designed to assess the tolerance, safety, and preliminary efficacy of XG0201 in adult female patients. While its exact chemical structure and primary molecular target have not been widely disclosed in public pharmacological databases, its clinical context suggests it may function as a targeted therapy or a sensitizing agent designed to improve outcomes in HER2-positive central nervous system (CNS) disease.